Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 04 November, 2009 and appeared in  Issue 494Cardiovascular HealthType 2 DiabetesType 1 DiabetesPrevention

New Targets Found for Preventing Diabetes Complications

Researchers at Joslin Diabetes Center now have clarified the complications story by detecting a second, independent pathway, which offers new targets for preventing and treating diabetic eye disease.

Advertisement

In diabetes patients, high blood glucose levels can end up killing certain cells in the eyes and kidneys, which is why diabetes is the leading cause of adult blindness and of kidney failure. Years ago, scientists identified one main route for this destruction -- high glucose produces oxidative stress through the NF-kB molecular pathway -- but success has been elusive for drugs targeting that pathway.

George L. King, M.D., Joslin's Director of Research, head of the Dianne Hoppes Nunnally Laboratory and senior author on the paper stated that, "Previously it was thought that oxidants are the major pathway, but antioxidants don't seem to work in clinical trials." "That clinical observation made it clear that we don't know all the mechanisms involved," says Pedro Geraldes, Ph.D., lead author for the paper. Expanding the search for what goes wrong as glucose levels climb, Geraldes studied the effects on retinal pericytes (supportive tissue cells found near small blood vessels).

Scientists had long known that the protein PDGF, a growth factor, is essential to a cell-survival pathway that is required to keep these retinal cells alive. Working both in cultured cells and diabetic animals, Geraldes traced a molecular cascade that ends up increasing the expression of a novel target, the protein SHP-1, which de-activates PDGF activity and thus triggers cell death.

"What's exciting is that we finally have an explanation for why antioxidant drugs may not work, because there's a parallel pathway," says King, who is also Professor of Medicine at Harvard Medical School. "We'll need an inhibitor of SHP-1 together with antioxidants to have a realistic chance of preventing or stopping diabetic eye disease."

"We think this is also applicable to diabetic kidney disease, because we observed a similar increase in SHP-1 in the kidneys of diabetic animals," King adds. Additionally, understanding the role that SHP-1 plays in cell survival pathways may shed light on studies of cancer and other diseases, he says.

Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy, Geraldes, P. et al, published online by Nature Medicine November 1, 2009. DOI: 10.1038/nm.2052.

 

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 04 November, 2009 and appeared in  Issue 494Cardiovascular HealthType 2 DiabetesType 1 DiabetesPrevention

Past five issues: Diabetes Clinical Mastery Series Issue 85 | Issue 626 | Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 |

2012 Most Popular Articles:

ADA/EASD Issue New Hyperglycemia Management Guidelines
Posted April 26, 2012
Type 2 More Dangerous in Children
Posted May 03, 2012
It’s the Variety of Fruit-and-Veggie That Lower Diabetes Risk
Posted May 03, 2012
Questioning Carbohydrate Restriction in Diabetes Management
Posted May 18, 2012
Ultra-Long-Acting Insulin Degludec, Two New Studies
Posted April 26, 2012
Eating Low Glycemic Index Foods at Breakfast Can Control Blood Sugar throughout the Day
Posted April 18, 2012
Metformin May Treat a Leading Cause of Blindness
Posted May 10, 2012
A Candy Treatment that Fights Diabetes and May Replace TZD's?
Posted May 10, 2012
Metformin May Not Be the Golden Pill After All for Treating Type 2 Diabetes
Posted April 18, 2012
Doubts Over Long Term Effectiveness of Group Education for Diabetes Patients
Posted May 03, 2012

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Marilyn Porter, RD, CDE | Melissa Diane Smith | Paul Chous, M.A., OD | Philip A. Wood PhD | Sheri R. Colberg PhD | Sherri Shafer | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Now that once-weekly GLP-1 is available, which product are you recommending for your type 2 patients?

Navigate Diabetes In Control
Announcement:



Search Articles On Diabetes In Control